Sign inJoin waitlistJoin the waitlist

Pasi Jänne

, Director of the Lowe Center for Thoracic Oncology · Mass General Brigham

Credentials: · · ·

History

Lowe Center for Thoracic Oncology · Mass General Brigham
Present

Hematology and Medical Oncology
Dana-Farber Cancer Institute
1999–2002
Internal Medicine
Brigham and Women's Hospital
1996–1999
University of Pennsylvania
The Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania
1992–1996

Research

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
Science · 2004 · 7,995 citations
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Science · 2007 · Last of 19 authors · 3,888 citations
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
New England Journal of Medicine · 2010 · 3,649 citations

BJ
Bruce Johnson
79 papers
Lynette Sholl
62 papers · 2 as a fellow
Geoffrey Oxnard
48 papers
MA
Mark Awad
44 papers
Kwok-Kin Wong
43 papers
JE
Jeffrey Engelman
39 papers · 6 as a fellow
David Jackman
32 papers · 3 as a fellow
Matthew Meyerson
32 papers
NL
Neal Lindeman
28 papers
David Barbie
26 papers
Geoffrey Shapiro
26 papers
Biagio Ricciuti
24 papers · 20 as a resident

Grants

Dana Farber/Harvard Cancer Center SPORE in Lung Cancer
National Cancer Institute · P50
Project lead · $1.9M · Dana-Farber Cancer Inst
2022–2027
Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance
National Cancer Institute · R35
Contact PI · $7.2M · Dana-Farber Cancer Inst
2018–2025
Targeting ALK Through Degradation and Allosteric Inhibitors
National Cancer Institute · R01
Contact PI · $4.6M · Stanford University
2009–2023
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma
National Cancer Institute · P01
Project lead · $3.3M · Dana-Farber Cancer Inst
2012–2023

Clinical trials

Biology of Young Lung Cancer Study: The YOUNG LUNG Study
Principal investigator · Recruiting
Dana-Farber Cancer Institute
2023–2027
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
Principal investigator · Active not recruiting · Phase 1, Phase 2
Dizal Pharmaceuticals
2019–2026
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
Principal investigator · Active not recruiting · Phase 3
AstraZeneca
2019–2027
Osimertinib In EGFR Mutant Lung Cancer
Principal investigator · Active not recruiting · Phase 2
Dana-Farber Cancer Institute
2018–2028